Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck, M Luft, A Szczesna, A Havel, L Kim, S Akerley, W Pietanza, M Wu, Y Zielinski, C Thomas, M
Reck, M
Luft, A
Szczesna, A
Havel, L
Kim, S
Akerley, W
Pietanza, M
Wu, Y
Zielinski, C
Thomas, M
Citations
Altmetric:
Abstract
Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC.
Description
Date
2016-07-25
Publisher
Collections
Keywords
Type
Article
Citation
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. 2016: J Clin Oncol